CHiR Therapy for Elderly DLBCL Intolerant to Chemo

Phase 2

Recruiting

• Conditions: Diffuse Large B-Cell Lymphoma
• Interventions: Drug: CHiR-DEL

• Registration Number: NCT06764017
• Lead Sponsor: First Affiliated Hospital of Ningbo University

Brief Summary

The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-01
• Study First Submitted: 2025-01-03
• Study First Submitted QC: 2025-01-03
• Study First Posted: 2025-01-08
• Study Start: 2025-02-01
• Last Update Submitted: 2025-03-16
• Last Update Posted: 2025-03-19
• Primary Completion: 2026-12-31
• Study Completion: 2027-08-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CHiR	CHiR-DEL	The combined regimen of chidamide, zanubrutinib, and lenalidomide (CHiR) is employed to treat elderly patients with double-expressor lymphoma. This study aims to explore the efficacy and safety of this regimen in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.

Primary Outcome Measures

Name	Time	Method
the complete remission rate (CRR)	Each cycle consists of 21 days, with a total of 8 cycles.	The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.

Trial Locations

Locations (1)

The First Affiliated Hospital of Ningbo University; 🇨🇳 Ningbo, Zhejiang, China